Wir sind mit live! Mehr erfahren
ANIP-Symbol

ANI Pharmaceuticals

72,29 USD
+0,01
0,01 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
1 Tag
0,01 %
5 Tage
-2,31 %
1 Monat
-1,77 %
3 Monate
-11,76 %
6 Monate
-7,4 %
Seit Jahresbeginn
-7,83 %
1 Jahr
-21,38 %
5 Jahre
91,4 %
10 Jahre
11,44 %
 

Profil: ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Mitarbeiter: 970

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 31,8 %
Neutral 54,5 %
Negativ 13,6 %
Positiv
Zacks Investment Research
vor 3 Tagen
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Positiv
Zacks Investment Research
vor 3 Tagen
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Neutral
GlobeNewsWire
vor 16 Tagen
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Neutral
Zacks Investment Research
vor 18 Tagen
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Positiv
Seeking Alpha
vor 22 Tagen
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
Neutral
GlobeNewsWire
vor 23 Tagen
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®.
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
Neutral
Seeking Alpha
letzten Monat
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
letzten Monat
ANI Pharmaceuticals to Present at September Investor Conferences
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
ANI Pharmaceuticals to Present at September Investor Conferences
Neutral
GlobeNewsWire
letzten Monat
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
Negativ
Zacks Investment Research
vor 2 Monaten
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Kursdiagramme mit Lightweight Charts™ umgesetzt